These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 27868471)

  • 41. Favorable response of relapsed/refractory gray-zone lymphoma to brentuximab vedotin.
    Li J; Sim J; Leung AYH; Kwong YL
    Ann Hematol; 2018 Mar; 97(3):551-554. PubMed ID: 29198035
    [No Abstract]   [Full Text] [Related]  

  • 42. Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.
    Alig SK; Dreyling M; Seppi B; Aulinger B; Witkowski L; Rieger CT
    Eur J Haematol; 2015 Jun; 94(6):554-7. PubMed ID: 24913471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
    Shea L; Mehta-Shah N
    Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.
    Bröckelmann PJ; Zagadailov EA; Corman SL; Chirikov V; Johnson C; Macahilig C; Seal B; Dalal MR; Illidge T
    Eur J Haematol; 2017 Dec; 99(6):553-558. PubMed ID: 28949403
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies.
    Fabbri A; Cencini E; Gozzetti A; Schiattone L; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(7):886-895. PubMed ID: 27592544
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
    Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
    Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.
    Gotlib J; Baird JH; George TI; Langford C; Reyes I; Abuel J; Perkins C; Schroeder K; Bose P; Verstovsek S
    Blood Adv; 2019 Aug; 3(15):2264-2271. PubMed ID: 31350306
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin.
    Goyal A; Hordinsky M; Lazaryan A
    Dermatol Ther; 2019 Mar; 32(2):e12835. PubMed ID: 30659762
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sézary Syndrome with Nodal CD30-positive Manifestation Treated with Brentuximab Vedotin and Extracorporeal Photopheresis.
    Behle V; von Braunmühl T; Sayehli C; Gesierich A; Goebeler M; Geissinger E; Wobser M
    Acta Derm Venereol; 2017 Aug; 97(8):973-975. PubMed ID: 28512672
    [No Abstract]   [Full Text] [Related]  

  • 50. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
    Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines.
    Schönberger S; van Beekum C; Götz B; Nettersheim D; Schorle H; Schneider DT; Casati A; Craveiro RB; Calaminus G; Dilloo D
    J Cell Mol Med; 2018 Jan; 22(1):568-575. PubMed ID: 28941150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.
    Ward JP; Berrien-Elliott MM; Gomez F; Luo J; Becker-Hapak M; Cashen AF; Wagner-Johnston ND; Maddocks K; Mosior M; Foster M; Krysiak K; Schmidt A; Skidmore ZL; Desai S; Watkins MP; Fischer A; Griffith M; Griffith OL; Fehniger TA; Bartlett NL
    Blood; 2022 Mar; 139(13):1999-2010. PubMed ID: 34780623
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.
    Abdulla M; Laszlo S; Triumf J; Hedström G; Berglund M; Enblad G; Amini RM
    Acta Oncol; 2016; 55(9-10):1126-1131. PubMed ID: 27549735
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding.
    Al-Rohil RN; Torres-Cabala CA; Patel A; Tetzlaff MT; Ivan D; Nagarajan P; Curry JL; Miranda RN; Duvic M; Prieto VG; Aung PP
    J Cutan Pathol; 2016 Dec; 43(12):1161-1166. PubMed ID: 27531242
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Brentuximab vedotin.
    Deng C; Pan B; O'Connor OA
    Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
    Eyre TA; Phillips EH; Linton KM; Arumainathan A; Kassam S; Gibb A; Allibone S; Radford J; Peggs K; Burton C; Stewart G; LeDieu R; Booth C; Osborne WL; Miall F; Eyre DW; Ardeshna KM; Collins GP
    Br J Haematol; 2017 Nov; 179(3):471-479. PubMed ID: 28857136
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic significance of CD30 expression in diffuse large B-cell lymphoma: A systematic review with meta-analysis.
    Rodrigues-Fernandes CI; Abreu LG; Radhakrishnan R; Perez DEDC; Amaral-Silva GK; Gondak RO; Rahimi S; Brennan PA; Fonseca FP; Vargas PA
    J Oral Pathol Med; 2021 Jul; 50(6):587-593. PubMed ID: 34101913
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.
    Li H; Han TH; Hunder NN; Jang G; Zhao B
    J Clin Pharmacol; 2017 Sep; 57(9):1148-1158. PubMed ID: 28513851
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Wagner-Johnston ND; Goy A; Rodriguez MA; Ehmann WC; Hamlin PA; Radford J; Thieblemont C; Suh C; Sweetenham J; Huang Y; Sullivan ST; Vandendries ER; Gisselbrecht C
    Leuk Lymphoma; 2015; 56(10):2863-9. PubMed ID: 25707288
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
    Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K
    BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.